OneMedNet Corp (NASDAQ: ONMD) has seen notable insider activity following substantial share acquisitions by director and ten percent owner Kosasa Thomas. Mr. Thomas completed two separate investment rounds through subscription agreements, totaling roughly $750,000 in capital deployed into the company's common stock.
Detailed Breakdown of Transactions
The first phase of this insider activity took place on February 6, 2026. During this transaction, Mr. Thomas acquired 595,238 shares at a price of $0.84 per share. This specific movement was facilitated through a subscription agreement with OneMedNet and constituted a $500,000 investment. Following the completion of this purchase, Mr. Thomas's direct holdings rose to 16,380,429 shares.
The second phase occurred on April 23, 2026, when Mr. Thomas purchased an additional 280,898 shares. These shares were acquired at $0.89 per share via another subscription agreement, representing a $250,000 investment. This subsequent transaction brought his total direct ownership to 16,661,327 shares.
According to filings, the pricing for these acquisitions was determined based on the volume-weighted average price (VWAP) observed during the 10 trading days immediately preceding each respective purchase date.
Operational and Financial Performance
Despite recent stock price fluctuations, OneMedNet has reported significant shifts in its financial metrics. The company's Real-World Data revenue saw a substantial increase of 329%, climbing to $1.25 million in 2025 from a baseline of $292,000 in 2024. During the fourth quarter, revenue was reported at $890,000.
On the balance sheet, OneMedNet has made strides in liability management, reducing its liabilities by 74%, falling from $19.7 million to $5.1 million. Furthermore, the company's shareholder deficit improved from $(16.0) million to $(3.0) million.
The company is also expanding its strategic footprint through several data-focused initiatives:
- Partnerships: Collaborations have been established with Inka Health for oncology data access and with ViuHealth to broaden autoimmune disease data on the iRWD platform.
- Infrastructure: OneMedNet is utilizing Palantir Foundry to support its various data initiatives.
- Commercialization: The firm has moved into the next stage of its commercial platform, focusing on converting customer evaluations into commercial subscriptions and securing multi-year deals that provide millions in recurring revenue.
Key Market Drivers and Sector Impact
Strategic Growth in Health Data: OneMedNet's focus on Real-World Data (RWD) through its iRWD platform highlights a significant trend within the healthcare technology and data analytics sectors. The ability to convert evaluations into multi-year recurring revenue streams indicates an attempt to build a more predictable commercial model.
Financial Restructuring: The dramatic reduction in liabilities and the narrowing of the shareholder deficit suggest an intensive focus on balance sheet strengthening, which impacts the broader micro-cap healthcare services market.
Risks and Uncertainties
Regulatory Compliance Risk: OneMedNet has received a notice from Nasdaq regarding non-compliance with minimum bid price requirements. The company has until October 12, 2026, to address this issue and regain compliance, posing a risk to its listing status.
Valuation Discrepancy: There is a noted gap between the current trading price of $0.89 and the calculated Fair Value of $0.79, suggesting that investors in the small-cap biotech/data sector may face valuation risks if the stock remains overvalued relative to its fundamentals.